$4.85
+0.04
(+0.83%)▲
4.12%
Downside
Day's Volatility :5.3%
Upside
1.22%
65.77%
Downside
52 Weeks Volatility :75.59%
Upside
28.68%
Period | Prelude Therapeutics Inc | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | 29.33% | 5.1% | 0.0% |
6 Months | 10.73% | 4.9% | 0.0% |
1 Year | 31.08% | 16.6% | 0.0% |
3 Years | -87.19% | 13.2% | -22.3% |
Market Capitalization | 266.9M |
Book Value | $3.31 |
Earnings Per Share (EPS) | -1.77 |
Wall Street Target Price | 5.8 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -35.22% |
Return On Equity TTM | -58.45% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -140.8M |
Diluted Eps TTM | -1.77 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.83 |
EPS Estimate Next Year | -1.6 |
EPS Estimate Current Quarter | -0.43 |
EPS Estimate Next Quarter | -0.43 |
What analysts predicted
Upside of 19.59%
Sell
Neutral
Buy
Prelude Therapeutics Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Prelude Therapeutics Inc | -4.9% | 10.73% | 31.08% | -87.19% | -81.49% |
![]() Regeneron Pharmaceuticals, Inc. | 5.97% | 16.25% | 37.11% | 69.18% | 305.56% |
![]() Novo Nordisk A/s | 9.99% | -3.52% | 34.24% | 158.74% | 417.73% |
![]() Alnylam Pharmaceuticals, Inc. | -5.15% | 64.67% | 22.72% | 31.08% | 198.44% |
![]() Vertex Pharmaceuticals Incorporated | 0.45% | 14.0% | 36.06% | 143.5% | 167.72% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Prelude Therapeutics Inc | NA | NA | NA | -1.83 | -0.58 | -0.35 | NA | 3.31 |
![]() Regeneron Pharmaceuticals, Inc. | 29.93 | 29.93 | 1.54 | 45.05 | 0.17 | 0.08 | NA | 261.41 |
![]() Novo Nordisk A/s | 44.01 | 44.01 | 1.98 | 3.44 | 0.89 | 0.23 | 0.01 | 25.24 |
![]() Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.55 | -15.01 | 0.02 | NA | -0.02 |
![]() Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.57 | 0.32 | -0.03 | 0.13 | NA | 57.26 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Prelude Therapeutics Inc | Sell | $266.9M | -81.49% | NA | 0.0% |
![]() Regeneron Pharmaceuticals, Inc. | Buy | $124.7B | 305.56% | 29.93 | 32.04% |
![]() Novo Nordisk A/s | Buy | $585.3B | 417.73% | 44.01 | 34.84% |
![]() Alnylam Pharmaceuticals, Inc. | Buy | $32.3B | 198.44% | NA | -3.11% |
![]() Vertex Pharmaceuticals Incorporated | Buy | $120.9B | 167.72% | 32.84 | -4.74% |
Insights on Prelude Therapeutics Inc
In the last 1 year, Regeneron Pharmaceuticals, Inc. has given 37.1% return, outperforming this stock by 6.0%
In the last 3 years, Novo Nordisk A/s has given 69.2% return, outperforming this stock by 156.4%
Orbimed Advisors, LLC
Baker Bros Advisors LP
Deerfield Management Co
Boxer Capital LLC
BlackRock Inc
Vanguard Group Inc
prelude therapeutics incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule therapies optimized to target the key driver mechanisms in cancers. it is developing prt543 that is in phase 1 clinical trials in select solid tumors and myeloid malignancies in patients who are refractory to or intolerant of established therapies; and prt811, which is in phase 1 clinical trials in solid tumors, including glioblastoma multiforme and primary central nervous system lymphomas. the company is also developing prt1419, a potent and selective inhibitor of the anti-apoptotic protein; prt2527, a potent inhibitor of cdk9 that exhibits high kinome selectivity; prt-sca2 for multiple genomically selected cancers; and prt-k4 for solid tumors. prelude therapeutics incorporated was founded in 2016 and is based in wilmington, delaware.
Organization | Prelude Therapeutics Inc |
Employees | 128 |
CEO | Dr. Krishna Vaddi D.V.M., Ph.D. |
Industry | Health Technology |
A Spac I Acquisition Corp
$4.85
+0.83%
Keyarch Acquisition Corp
$4.85
+0.83%
Connexa Sports Technologies Inc
$4.85
+0.83%
Us Value Etf
$4.85
+0.83%
First Wave Biopharma Inc
$4.85
+0.83%
Global X Msci Next Emerging
$4.85
+0.83%
Fat Projects Acquisition Corp
$4.85
+0.83%
Capital Link Global Fintech
$4.85
+0.83%
Applied Uv Inc
$4.85
+0.83%